MARKET

CALA

CALA

Calithera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.810
+0.340
+7.61%
After Hours: 4.810 0 0.00% 16:00 03/27 EDT
OPEN
4.610
PREV CLOSE
4.470
HIGH
5.29
LOW
4.450
VOLUME
945.07K
TURNOVER
--
52 WEEK HIGH
8.04
52 WEEK LOW
2.450
MARKET CAP
311.13M
P/E (TTM)
-2.4471
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CALA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CALA stock price target is 10.75 with a high estimate of 20.00 and a low estimate of 7.00.

EPS

CALA News

More
  • Have Insiders Been Buying Calithera Biosciences, Inc. (NASDAQ:CALA) Shares?
  • Simply Wall St. · 1d ago
  • Edited Transcript of CALA earnings conference call or presentation 11-Mar-20 9:00pm GMT
  • Thomson Reuters StreetEvents · 1d ago
  • Stifel likes bluebird bio in premarket analyst action
  • Seeking Alpha - Article · 2d ago
  • Week 12 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
  • Seeking Alpha - Article · 03/15 17:23

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About CALA

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
More

Webull offers kinds of Calithera Biosciences Inc stock information, including NASDAQ:CALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALA stock news, and many more online research tools to help you make informed decisions.